Aclaris Therapeutics, Inc. (ACRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACRS POWR Grades
- ACRS scores best on the Growth dimension, with a Growth rank ahead of 54.6% of US stocks.
- The strongest trend for ACRS is in Stability, which has been heading up over the past 179 days.
- ACRS's current lowest rank is in the Value metric (where it is better than 6.76% of US stocks).
ACRS Stock Summary
- For ACRS, its debt to operating expenses ratio is greater than that reported by merely 5.72% of US equities we're observing.
- With a price/sales ratio of 161.77, Aclaris Therapeutics Inc has a higher such ratio than 98.32% of stocks in our set.
- With a year-over-year growth in debt of -93.84%, Aclaris Therapeutics Inc's debt growth rate surpasses only 2.06% of about US stocks.
- Stocks that are quantitatively similar to ACRS, based on their financial statements, market capitalization, and price volatility, are AKTS, EDIT, FREQ, TBPH, and SAGE.
- ACRS's SEC filings can be seen here. And to visit Aclaris Therapeutics Inc's official web site, go to www.aclaristx.com.
ACRS Valuation Summary
- In comparison to the median Healthcare stock, ACRS's price/earnings ratio is 138.36% lower, now standing at -14.
- ACRS's price/sales ratio has moved NA NA over the prior 72 months.
- ACRS's EV/EBIT ratio has moved down 1.9 over the prior 72 months.
Below are key valuation metrics over time for ACRS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACRS | 2021-08-31 | 149.7 | 4.2 | -14.0 | -12.6 |
| ACRS | 2021-08-30 | 142.2 | 4.0 | -13.3 | -11.9 |
| ACRS | 2021-08-27 | 144.9 | 4.1 | -13.6 | -12.1 |
| ACRS | 2021-08-26 | 131.9 | 3.7 | -12.4 | -10.9 |
| ACRS | 2021-08-25 | 136.9 | 3.9 | -12.8 | -11.4 |
| ACRS | 2021-08-24 | 135.3 | 3.8 | -12.7 | -11.2 |
ACRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ACRS has a Quality Grade of D, ranking ahead of 11.05% of graded US stocks.
- ACRS's asset turnover comes in at 0.045 -- ranking 329th of 680 Pharmaceutical Products stocks.
- IONS, INBP, and CYTK are the stocks whose asset turnover ratios are most correlated with ACRS.
The table below shows ACRS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.045 | 0.255 | -0.798 |
| 2021-03-31 | 0.070 | 0.261 | -1.118 |
| 2020-12-31 | 0.080 | 0.208 | -1.456 |
| 2020-09-30 | 0.068 | 0.187 | -1.659 |
| 2020-06-30 | 0.050 | 0.184 | -1.897 |
| 2020-03-31 | 0.065 | 0.377 | -2.002 |
ACRS Price Target
For more insight on analysts targets of ACRS, see our ACRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $34.80 | Average Broker Recommendation | 1.25 (Strong Buy) |
ACRS Stock Price Chart Interactive Chart >
ACRS Price/Volume Stats
| Current price | $16.95 | 52-week high | $19.97 |
| Prev. close | $16.80 | 52-week low | $9.26 |
| Day low | $16.70 | Volume | 351,446 |
| Day high | $17.05 | Avg. volume | 443,323 |
| 50-day MA | $15.39 | Dividend yield | N/A |
| 200-day MA | $14.27 | Market Cap | 1.13B |
Aclaris Therapeutics, Inc. (ACRS) Company Bio
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, Pennsylvania.
Latest ACRS News From Around the Web
Below are the latest news stories about Aclaris Therapeutics Inc that investors may wish to consider to help them evaluate ACRS as an investment opportunity.
Aclaris Therapeutics GAAP EPS of -$0.37 misses by $0.01, revenue of $1.5M misses by $0.3MAclaris Therapeutics press release (ACRS): Q4 GAAP EPS of -$0.37 misses by $0.01.Revenue of $1.5M (-5.1% Y/Y) misses by $0.3M. |
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue EstimatesAclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateWAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2021 and provided a corporate update. “2021 was a tremendous year for the progression of our drug development pipeline, and I’m very proud of what our team has accomplished,” said Dr. Neal Walker, President & CEO |
Aclaris Therapeutics Q4 2021 Earnings Preview (NASDAQ:ACRS)Aclaris Therapeutics (NASDAQ:ACRS) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.36 and the consensus |
Those who invested in Aclaris Therapeutics (NASDAQ:ACRS) three years ago are up 97%By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at... |
ACRS Price Returns
| 1-mo | 7.01% |
| 3-mo | 59.15% |
| 6-mo | 33.36% |
| 1-year | 12.18% |
| 3-year | 1,947.84% |
| 5-year | -32.42% |
| YTD | 16.57% |
| 2021 | 124.73% |
| 2020 | 242.33% |
| 2019 | -74.42% |
| 2018 | -70.03% |
| 2017 | -9.14% |
Continue Researching ACRS
Want to see what other sources are saying about Aclaris Therapeutics Inc's financials and stock price? Try the links below:Aclaris Therapeutics Inc (ACRS) Stock Price | Nasdaq
Aclaris Therapeutics Inc (ACRS) Stock Quote, History and News - Yahoo Finance
Aclaris Therapeutics Inc (ACRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...